FibroGen Inc. (NASDAQ:FGEN) CEO Thomas B. Neff sold 37,798 shares of the firm’s stock in a transaction that occurred on Tuesday, November 29th. The shares were sold at an average price of $22.80, for a total value of $861,794.40. Following the transaction, the chief executive officer now directly owns 3,331,639 shares of the company’s stock, valued at approximately $75,961,369.20. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Shares of FibroGen Inc. (NASDAQ:FGEN) opened at 22.15 on Thursday. The company’s market cap is $1.40 billion. The firm has a 50 day moving average price of $19.11 and a 200-day moving average price of $18.61. FibroGen Inc. has a 12-month low of $14.38 and a 12-month high of $31.90.

FibroGen (NASDAQ:FGEN) last released its earnings results on Tuesday, November 8th. The biopharmaceutical company reported ($0.38) EPS for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.21. The firm had revenue of $30.10 million for the quarter, compared to analysts’ expectations of $24.30 million. FibroGen had a negative return on equity of 40.38% and a negative net margin of 45.93%. On average, equities analysts expect that FibroGen Inc. will post ($0.99) earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for FibroGen (NASDAQ:FGEN)

ILLEGAL ACTIVITY WARNING: This report was first published by Daily Political and is the propert of of Daily Political. If you are viewing this report on another site, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be viewed at http://www.dailypolitical.com/2016/12/01/fibrogen-inc-fgen-ceo-thomas-b-neff-sells-37798-shares.html.

A number of research firms recently weighed in on FGEN. Zacks Investment Research raised FibroGen from a “hold” rating to a “buy” rating and set a $25.00 price objective for the company in a research report on Friday, November 11th. Leerink Swann reaffirmed a “buy” rating and set a $52.00 price objective on shares of FibroGen in a research report on Wednesday, November 9th. Finally, Credit Suisse Group AG reaffirmed a “buy” rating and set a $37.00 price objective on shares of FibroGen in a research report on Tuesday, August 9th.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Candriam Luxembourg S.C.A. boosted its position in FibroGen by 77.5% in the third quarter. Candriam Luxembourg S.C.A. now owns 481,000 shares of the biopharmaceutical company’s stock worth $9,957,000 after buying an additional 210,000 shares in the last quarter. Doheny Asset Management CA raised its stake in shares of FibroGen by 44.1% in the third quarter. Doheny Asset Management CA now owns 28,000 shares of the biopharmaceutical company’s stock worth $580,000 after buying an additional 8,575 shares during the last quarter. Panagora Asset Management Inc. raised its stake in shares of FibroGen by 274.5% in the third quarter. Panagora Asset Management Inc. now owns 51,802 shares of the biopharmaceutical company’s stock worth $1,072,000 after buying an additional 37,968 shares during the last quarter. Hillhouse Capital Management Ltd. purchased a new stake in shares of FibroGen during the third quarter worth about $10,612,000. Finally, The Manufacturers Life Insurance Company purchased a new stake in shares of FibroGen during the third quarter worth about $753,000. 48.26% of the stock is currently owned by hedge funds and other institutional investors.

FibroGen Company Profile

FibroGen, Inc is a research-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200.

5 Day Chart for NASDAQ:FGEN

Receive News & Ratings for FibroGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.